688658 悦康药业
交易中 01-30 10:31:21
资讯
新帖
简况
增长失速、盈利触底 悦康药业(688658.SH)赴港为求“续命”?
智通财经 · 01-28 11:38
增长失速、盈利触底 悦康药业(688658.SH)赴港为求“续命”?
每周股票复盘:悦康药业(688658)预计2026年日常关联交易24,156万元
证券之星 · 01-25
每周股票复盘:悦康药业(688658)预计2026年日常关联交易24,156万元
业绩连续三年下滑 悦康药业(688658.SH)“救火式”赴港上市?
智通财经 · 01-23
业绩连续三年下滑 悦康药业(688658.SH)“救火式”赴港上市?
1月19日悦康药业跌5.21%,富国精准医疗混合A基金重仓该股
证券之星 · 01-19
1月19日悦康药业跌5.21%,富国精准医疗混合A基金重仓该股
悦康药业筹划H股上市:新增长叙事挑战重重 左手募资右手大额分红前次募投项目多次延期
新浪证券 · 01-16
悦康药业筹划H股上市:新增长叙事挑战重重 左手募资右手大额分红前次募投项目多次延期
1月9日悦康药业涨17.13%,富国精准医疗混合A基金重仓该股
中金财经 · 01-09
1月9日悦康药业涨17.13%,富国精准医疗混合A基金重仓该股
悦康药业(688658.SH)营收净利三连降 于伟仕家族为何还分红超4亿?
智通财经 · 01-08
悦康药业(688658.SH)营收净利三连降 于伟仕家族为何还分红超4亿?
每周股票复盘:悦康药业(688658)递交H股上市申请
证券之星 · 01-02
每周股票复盘:悦康药业(688658)递交H股上市申请
悦康药业向港交所提交上市申请
第一财经 · 2025-12-29
悦康药业向港交所提交上市申请
每周股票复盘:悦康药业(688658)拟发行H股赴港上市
证券之星 · 2025-12-28
每周股票复盘:悦康药业(688658)拟发行H股赴港上市
悦康药业(688658)披露拟发行H股并在港交所上市,12月22日股价上涨2.75%
证券之星 · 2025-12-22
悦康药业(688658)披露拟发行H股并在港交所上市,12月22日股价上涨2.75%
悦康药业(688658.SH):子公司YKYY032注射液获国家药品监督管理局和FDA临床试验批准
智通财经 · 2025-12-19
悦康药业(688658.SH):子公司YKYY032注射液获国家药品监督管理局和FDA临床试验批准
悦康药业,爆亏1.5亿却要赴港上市,开源证券预测明年还是亏损?
市场资讯 · 2025-12-19
悦康药业,爆亏1.5亿却要赴港上市,开源证券预测明年还是亏损?
悦康药业(688658)披露拟发行H股并在港交所上市,12月16日股价下跌4.31%
证券之星 · 2025-12-16
悦康药业(688658)披露拟发行H股并在港交所上市,12月16日股价下跌4.31%
12月15日悦康药业跌5.54%,富国精准医疗混合A基金重仓该股
证券之星 · 2025-12-15
12月15日悦康药业跌5.54%,富国精准医疗混合A基金重仓该股
悦康药业(688658.SH):注射用YKYY031用于开展晚期实体瘤临床试验获得批准
智通财经 · 2025-12-12
悦康药业(688658.SH):注射用YKYY031用于开展晚期实体瘤临床试验获得批准
12月12日悦康药业跌8.49%,富国精准医疗混合A基金重仓该股
证券之星 · 2025-12-12
12月12日悦康药业跌8.49%,富国精准医疗混合A基金重仓该股
悦康药业拟增选两名董事并调整提名委员会,为H股上市完善治理
中金财经 · 2025-12-07
悦康药业拟增选两名董事并调整提名委员会,为H股上市完善治理
悦康药业(688658.SH)筹划发行H股股票并在香港联交所上市
智通财经 · 2025-12-05
悦康药业(688658.SH)筹划发行H股股票并在香港联交所上市
悦康药业(688658.SH)子公司YKYY018雾化吸入剂获临床试验批准
智通财经网 · 2025-12-02
悦康药业(688658.SH)子公司YKYY018雾化吸入剂获临床试验批准
加载更多
公司概况
公司名称:
悦康药业集团股份有限公司
所属行业:
医药制造业
上市日期:
2020-12-24
主营业务:
悦康药业集团股份有限公司的主营业务是原料药及制剂相关产品的生产和销售。公司的主要产品是银杏叶提取物注射液、天麻素注射液、注射用兰索拉唑、奥美拉唑肠溶胶囊、盐酸二甲双胍缓释片、注射用头孢呋辛钠、注射用头孢曲松钠。公司连续多年荣获工信部医药工业百强和中国医药研发产品线最佳工业企业的殊荣,入榜《2025年中国药品研发综合实力排行榜TOP100》并荣登《2025中国中药研发实力排行榜》第六名。2024年,公司“头孢菌素类抗生素原料药关键技术研究及产业化应用”项目,荣获河南省科学技术进步三等奖,彰显了公司在医药领域的卓越成就和创新实力。
发行价格:
24.36
{"stockData":{"symbol":"688658","market":"SH","secType":"STK","nameCN":"悦康药业","latestPrice":24.76,"timestamp":1769740281000,"preClose":24.47,"halted":0,"volume":4775844,"delay":0,"changeRate":0.0119,"floatShares":450000000,"shares":450000000,"eps":-0.52,"marketStatus":"交易中","change":0.29,"latestTime":"01-30 10:31:21","open":24.5,"high":25.69,"low":24.48,"amount":119000000,"amplitude":0.0494,"askPrice":24.76,"askSize":9,"bidPrice":24.74,"bidSize":43,"shortable":0,"etf":0,"ttmEps":-0.52,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1769743800000},"marketStatusCode":2,"adr":0,"adjPreClose":24.47,"symbolType":"stock_kcb","openAndCloseTimeList":[[1769736600000,1769743800000],[1769749200000,1769756400000]],"highLimit":26.92,"lowLimit":22.02,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":450000000,"isCdr":false,"pbRate":3.21,"roa":"--","roe":"--","epsLYR":0.28,"committee":0.526462,"marketValue":11142000000,"turnoverRate":0.0106,"status":0,"floatMarketCap":11142000000},"requestUrl":"/m/hq/s/688658","defaultTab":"news","newsList":[{"id":"2606766618","title":"增长失速、盈利触底 悦康药业(688658.SH)赴港为求“续命”?","url":"https://stock-news.laohu8.com/highlight/detail?id=2606766618","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606766618?lang=zh_cn&edition=full","pubTime":"2026-01-28 11:38","pubTimestamp":1769571493,"startTime":"0","endTime":"0","summary":"2026年1月初,科创板上市的化学药企悦康药业集团股份有限公司,已正式向港交所递交了H股上市申请。公司营收已连续三年下滑,从2022年的45.42亿元降至2024年的37.81亿元。2025年一季度的亏损表明,阵痛远未结束。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1398401.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688658","BK0239"],"gpt_icon":0},{"id":"2606373062","title":"每周股票复盘:悦康药业(688658)预计2026年日常关联交易24,156万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606373062","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606373062?lang=zh_cn&edition=full","pubTime":"2026-01-25 03:32","pubTimestamp":1769283132,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘,悦康药业报收于27.15元,较上周的28.59元下跌5.04%。本周,悦康药业1月21日盘中最高价报28.68元。本周关注点公司公告汇总:预计2026年度日常关联交易总额为24,156.00万元。会议将审议《关于公司2026年度日常关联交易预计的议案》,该议案需对中小投资者单独计票,并实行关联股东回避表决。公司预计2026年度日常关联交易总额为24,156.00万元,涵盖向关联方采购原材料、商品、接受服务、销售产品以及房产租赁等事项。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500001273.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688658"],"gpt_icon":0},{"id":"2605042024","title":"业绩连续三年下滑 悦康药业(688658.SH)“救火式”赴港上市?","url":"https://stock-news.laohu8.com/highlight/detail?id=2605042024","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605042024?lang=zh_cn&edition=full","pubTime":"2026-01-23 16:25","pubTimestamp":1769156754,"startTime":"0","endTime":"0","summary":"近日,悦康药业发布公告称,为进一步提高公司综合竞争力,提升公司国际品牌形象,同时更好地利用国际资本市场,多元化融资渠道,公司拟在境外发行股份(H股)并在港交所主板上市。2020年12月24日,悦康药业在上海证券交易所科创板上市。事实上,近年来悦康药业业绩已连续三年下滑。2025年,悦康药业业绩进一步下滑。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396648.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688658","BK0239"],"gpt_icon":0},{"id":"2604185930","title":"1月19日悦康药业跌5.21%,富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2604185930","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604185930?lang=zh_cn&edition=full","pubTime":"2026-01-19 15:37","pubTimestamp":1768808230,"startTime":"0","endTime":"0","summary":"证券之星消息,1月19日悦康药业跌5.21%,收盘报27.1元,换手率1.86%,成交量8.37万手,成交额2.29亿元。重仓悦康药业的前十大公募基金请见下表:该股最近90天内共有2家机构给出评级,买入评级2家。根据2025基金Q3季报公募基金重仓股数据,重仓该股的公募基金共21家,其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为34.91亿元,最新净值3.2156,较上一交易日下跌0.93%,近一年上涨49.34%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011900014458.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","BK0239"],"gpt_icon":0},{"id":"2603968033","title":"悦康药业筹划H股上市:新增长叙事挑战重重 左手募资右手大额分红前次募投项目多次延期","url":"https://stock-news.laohu8.com/highlight/detail?id=2603968033","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603968033?lang=zh_cn&edition=full","pubTime":"2026-01-16 15:43","pubTimestamp":1768549380,"startTime":"0","endTime":"0","summary":" 在登陆上海证券交易所科创板不足五年之际,悦康药业于近期发布公告称计划发行境外上市外资股(H股)并在香港联合交易所有限公司主板上市。公司表示,此举旨在进一步提升综合竞争力与国际品牌形象,并拓展国际资本市场融资渠道。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-01-16/doc-inhhnuux3992775.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688658"],"gpt_icon":0},{"id":"2602328172","title":"1月9日悦康药业涨17.13%,富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2602328172","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602328172?lang=zh_cn&edition=full","pubTime":"2026-01-09 15:53","pubTimestamp":1767945234,"startTime":"0","endTime":"0","summary":"证券之星消息,1月9日悦康药业涨17.13%创60日新高,收盘报31.79元,换手率4.45%,成交量20.04万手,成交额5.86亿元。重仓悦康药业的前十大公募基金请见下表:该股最近90天内共有2家机构给出评级,买入评级2家。根据2025基金Q3季报公募基金重仓股数据,重仓该股的公募基金共21家,其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为34.91亿元,最新净值3.2598,较上一交易日下跌0.01%,近一年上涨53.84%。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202601/09/20260109981127.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202601/09/20260109981127.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260109/31929452.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688658","BK0239"],"gpt_icon":0},{"id":"2601354509","title":"悦康药业(688658.SH)营收净利三连降 于伟仕家族为何还分红超4亿?","url":"https://stock-news.laohu8.com/highlight/detail?id=2601354509","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601354509?lang=zh_cn&edition=full","pubTime":"2026-01-08 16:52","pubTimestamp":1767862357,"startTime":"0","endTime":"0","summary":"港股生物医药板块迎来久违的上涨行情。百济神州、翰森制药等龙头股价节节攀升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390373.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688658"],"gpt_icon":0},{"id":"2600036316","title":"每周股票复盘:悦康药业(688658)递交H股上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2600036316","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600036316?lang=zh_cn&edition=full","pubTime":"2026-01-02 02:43","pubTimestamp":1767292989,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘,悦康药业报收于23.13元,较上周的22.52元上涨2.71%。本周,悦康药业12月25日盘中最高价报24.07元。悦康药业当前最新总市值101.75亿元,在化学制药板块市值排名52/150,在两市A股市值排名1883/5181。本周关注点公司公告汇总:悦康药业已向香港联交所递交H股发行上市申请,并刊发申请资料。本次发行上市尚需取得中国证监会、香港证监会、香港联交所等监管机构的批准或核准,存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000651.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","BK0239"],"gpt_icon":0},{"id":"2595735465","title":"悦康药业向港交所提交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2595735465","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595735465?lang=zh_cn&edition=full","pubTime":"2025-12-29 22:11","pubTimestamp":1767017460,"startTime":"0","endTime":"0","summary":"据港交所文件,悦康药业集团股份有限公司向港交所提交上市申请书,独家保荐人为中信证券。(本文来自第一财经)\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2025-12-29/doc-inhenrqi0053490.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-12-29/doc-inhenrqi0053490.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688658","HEXmain"],"gpt_icon":0},{"id":"2594247827","title":"每周股票复盘:悦康药业(688658)拟发行H股赴港上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2594247827","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594247827?lang=zh_cn&edition=full","pubTime":"2025-12-28 04:48","pubTimestamp":1766868489,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘,悦康药业报收于23.13元,较上周的22.52元上涨2.71%。本周,悦康药业12月25日盘中最高价报24.07元。本周关注点公司公告汇总:悦康药业拟发行H股股票并在香港联交所上市。公司公告汇总:悦康药业2025年第三次临时股东会出席股东代表股份占比53.6184%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800001242.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688658"],"gpt_icon":0},{"id":"2593351084","title":"悦康药业(688658)披露拟发行H股并在港交所上市,12月22日股价上涨2.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593351084","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593351084?lang=zh_cn&edition=full","pubTime":"2025-12-22 22:52","pubTimestamp":1766415132,"startTime":"0","endTime":"0","summary":"截至2025年12月22日收盘,悦康药业报收于23.14元,较前一交易日上涨2.75%,最新总市值为104.13亿元。该股当日开盘22.99元,最高23.72元,最低22.43元,成交额达1.2亿元,换手率为1.15%。会议表决方式符合法律规定,议案均获通过,无被否决议案。中小投资者对部分议案进行了单独计票。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200035587.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","BK0239","HEXmain"],"gpt_icon":0},{"id":"2592152396","title":"悦康药业(688658.SH):子公司YKYY032注射液获国家药品监督管理局和FDA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2592152396","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592152396?lang=zh_cn&edition=full","pubTime":"2025-12-19 16:39","pubTimestamp":1766133582,"startTime":"0","endTime":"0","summary":"智通财经APP讯,悦康药业 发布公告,公司子公司北京悦康科创医药科技股份有限公司、杭州天龙药业有限公司于近日获得国家药品监督管理局核准签发的关于YKYY032注射液用于治疗高脂蛋白血症的《药物临床试验批准通知书》。YKYY032注射液是一款偶联N-乙酰半乳糖胺配体的化学合成双链siRNA药物,通过RNA干扰机制特异性沉默LPA基因转录的mRNA,从源头阻断脂蛋白[Lp]生成,拟用于高脂蛋白血症治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383670.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"悦康药业(688658.SH):子公司YKYY032注射液获国家药品监督管理局和FDA临床试验批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688658","BK0239"],"gpt_icon":0},{"id":"2592713549","title":"悦康药业,爆亏1.5亿却要赴港上市,开源证券预测明年还是亏损?","url":"https://stock-news.laohu8.com/highlight/detail?id=2592713549","media":"市场资讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592713549?lang=zh_cn&edition=full","pubTime":"2025-12-19 06:58","pubTimestamp":1766098680,"startTime":"0","endTime":"0","summary":" 最近,科创板上市公司悦康药业正在紧锣密鼓地策划发行H股、赴港上市,目前已经聘请容诚(香港)会计师事务所有限公司作为专项审计机构。 也就是说,就连一贯以乐观预期为标签、且持续给出悦康药业买入评级的开源证券,都认为公司在2026年不大可能实现盈利了,仍将出现大额亏损。在这样的背景下,悦康药业还要赴港上市、更好地利用国际资本市场?","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-19/doc-inhchsqr6018516.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["161027","BK0239","688658"],"gpt_icon":0},{"id":"2591980018","title":"悦康药业(688658)披露拟发行H股并在港交所上市,12月16日股价下跌4.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591980018","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591980018?lang=zh_cn&edition=full","pubTime":"2025-12-16 22:21","pubTimestamp":1765894886,"startTime":"0","endTime":"0","summary":"近日,悦康药业集团股份有限公司发布2025年第三次临时股东会会议资料,宣布将召开临时股东会,审议关于公司发行H股股票并在香港联合交易所上市的议案。公告内容包括H股发行方案、募集资金使用计划、公司转为境外募集股份有限公司、H股发行决议有效期、授权董事会办理相关事宜、H股发行前滚存利润分配方案、制定H股上市后适用的公司章程及议事规则、内部治理制度,以及投保董事及高管责任保险、聘请审计机构等事项。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121600040875.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","HEXmain","BK0239"],"gpt_icon":0},{"id":"2591615557","title":"12月15日悦康药业跌5.54%,富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2591615557","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591615557?lang=zh_cn&edition=full","pubTime":"2025-12-15 15:36","pubTimestamp":1765784176,"startTime":"0","endTime":"0","summary":"证券之星消息,12月15日悦康药业跌5.54%,收盘报23.2元,换手率1.41%,成交量6.37万手,成交额1.51亿元。根据2025基金Q3季报公募基金重仓股数据,重仓该股的公募基金共21家,其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为34.91亿元,最新净值3.2964,较上一交易日下跌0.68%,近一年上涨37.14%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500012994.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","BK0239"],"gpt_icon":0},{"id":"2590740985","title":"悦康药业(688658.SH):注射用YKYY031用于开展晚期实体瘤临床试验获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2590740985","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590740985?lang=zh_cn&edition=full","pubTime":"2025-12-12 17:24","pubTimestamp":1765531478,"startTime":"0","endTime":"0","summary":"智通财经APP讯,悦康药业 发布公告,公司全资子公司北京悦康科创医药科技股份有限公司、杭州天龙药业有限公司于近日获得国家药品监督管理局核准签发的关于同意注射用YKYY031用于开展晚期实体瘤的《药物临床试验批准通知书》。注射用YKYY031是一种通用型mRNA肿瘤疫苗,拟用于晚期实体瘤的治疗。注射用YKYY031临床前研究充分证实其具备显著的有效性与良好的安全性,优势突出。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380927.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"悦康药业(688658.SH):注射用YKYY031用于开展晚期实体瘤临床试验获得批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688658"],"gpt_icon":0},{"id":"2590754675","title":"12月12日悦康药业跌8.49%,富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2590754675","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590754675?lang=zh_cn&edition=full","pubTime":"2025-12-12 15:36","pubTimestamp":1765524992,"startTime":"0","endTime":"0","summary":"证券之星消息,12月12日悦康药业跌8.49%,收盘报24.56元,换手率4.17%,成交量18.75万手,成交额4.59亿元。根据2025基金Q3季报公募基金重仓股数据,重仓该股的公募基金共21家,其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为34.91亿元,最新净值3.3191,较上一交易日上涨0.04%,近一年上涨38.76%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200018679.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688658"],"gpt_icon":0},{"id":"2589789188","title":"悦康药业拟增选两名董事并调整提名委员会,为H股上市完善治理","url":"https://stock-news.laohu8.com/highlight/detail?id=2589789188","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589789188?lang=zh_cn&edition=full","pubTime":"2025-12-07 10:37","pubTimestamp":1765075076,"startTime":"0","endTime":"0","summary":"中访网数据 悦康药业集团股份有限公司于2025年12月4日召开董事会,审议通过多项与未来H股上市相关的公司治理调整议案。核心决策包括:为完善H股上市后的治理结构,公司董事会成员拟由9名增至11名,并提名滕秀梅女士为执行董事、何敬丰先生为独立非执行董事,该任命需待股东大会批准及H股上市完成后生效。同时,公司计划调整董事会提名委员会成员,在H股上市后,委员会成员将调整为蒋斌(召集人)、于伟仕、于谦龙、谭勇及新提名的执行董事滕秀梅。此次人事变动旨在优化公司董事会构成,以符合联交所上市规则并提升治理水平,为公司后续在香港联合交易所的上市进程做准备。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251207/31849155.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","688658"],"gpt_icon":0},{"id":"2589898197","title":"悦康药业(688658.SH)筹划发行H股股票并在香港联交所上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2589898197","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589898197?lang=zh_cn&edition=full","pubTime":"2025-12-05 17:19","pubTimestamp":1764926347,"startTime":"0","endTime":"0","summary":"智通财经APP讯,悦康药业(688658.SH)发布公告,为进一步提高公司综合竞争力,提升公司国际品牌形象,同时更好地利用国际资本市场,多元化融资渠道,公司拟在境外发行股份(H股)并在香港联合交易所有限公司(简称“香港联交所”)主板上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378184.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688658","BK0239"],"gpt_icon":0},{"id":"2588771038","title":"悦康药业(688658.SH)子公司YKYY018雾化吸入剂获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2588771038","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588771038?lang=zh_cn&edition=full","pubTime":"2025-12-02 16:15","pubTimestamp":1764663318,"startTime":"0","endTime":"0","summary":"智通财经APP讯,悦康药业(688658.SH)发布公告,公司全资子公司北京悦康科创医药科技股份有限公司(简称“悦康科创”)于近日获得国家药品监督管理局(简称“NMPA”)核准签发的关于同意YKYY018雾化吸入剂用于与呼吸道合胞病毒患者接触后的暴露后预防和用于RSV感染的治疗的两份《药物临床试验批准通知书》,公司将开展本品I期临床试验。更多港股重磅资讯,下载智通财经app更多港股及海外理财资讯,请点击www.zhitongcaijing.com(搜索“智通财经”);欲加入智通港股投资群,请加智通客服微信(ztcjkf)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1376499.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","688658"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1769740286029,"stockEarnings":[{"period":"1week","weight":-0.0886},{"period":"1month","weight":0.0737},{"period":"3month","weight":0.1292},{"period":"6month","weight":-0.2758},{"period":"1year","weight":0.6658},{"period":"ytd","weight":0.0823}],"compareEarnings":[{"period":"1week","weight":0.0086},{"period":"1month","weight":0.0486},{"period":"3month","weight":0.0514},{"period":"6month","weight":0.168},{"period":"1year","weight":0.2791},{"period":"ytd","weight":0.0477}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"悦康药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"10690人(较上一季度减少8.39%)","perCapita":"42095股","listingDate":"2020-12-24","address":"北京市大兴区北京经济技术开发区宏达中路6号","registeredCapital":"45000万元","survey":" 悦康药业集团股份有限公司的主营业务是原料药及制剂相关产品的生产和销售。公司的主要产品是银杏叶提取物注射液、天麻素注射液、注射用兰索拉唑、奥美拉唑肠溶胶囊、盐酸二甲双胍缓释片、注射用头孢呋辛钠、注射用头孢曲松钠。公司连续多年荣获工信部医药工业百强和中国医药研发产品线最佳工业企业的殊荣,入榜《2025年中国药品研发综合实力排行榜TOP100》并荣登《2025中国中药研发实力排行榜》第六名。2024年,公司“头孢菌素类抗生素原料药关键技术研究及产业化应用”项目,荣获河南省科学技术进步三等奖,彰显了公司在医药领域的卓越成就和创新实力。","listedPrice":24.36},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"悦康药业(688658)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供悦康药业(688658)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"悦康药业,688658,悦康药业股票,悦康药业股票老虎,悦康药业股票老虎国际,悦康药业行情,悦康药业股票行情,悦康药业股价,悦康药业股市,悦康药业股票价格,悦康药业股票交易,悦康药业股票购买,悦康药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"悦康药业(688658)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供悦康药业(688658)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}